Lupin Secures U.S. FDA Approval For Sodium Zirconium Cyclosilicate

Lupin received U.S. FDA approval for generic Sodium Zirconium Cyclosilicate oral suspension, equivalent to AstraZeneca’s Lokelma for adult hyperkalemia treatment. The reference product had estimated U.S. annual sales of $568 million as of June 2026.